4-[4-[(R)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-ium-1-yl]butanoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[4-[(R)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-ium-1-yl]butanoate
• 化学式: C₂₁H₂₅ClN₂O₃
• 分子量: 388.894
• InChiKey: YWGDOWXRIALTES-OAQYLSRUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  62.7
• 氢给体数：
  1
• 氢受体数：
  5

ADMET

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用总结：目前没有报告在母亲使用bepotastine治疗期间母乳喂养的婴儿。由于眼部吸收有限，bepotastine预计不会对母乳喂养的婴儿产生任何不良反应。为了显著减少使用眼药水后到达母乳中的药物量，可以在眼角处对泪囊施加压力1分钟或更长时间，然后用吸水纸巾去除多余的溶液。 ◉ 对母乳喂养婴儿的影响：截至修订日期，未找到关于bepotastine的相关已发布信息。在一项电话随访研究中，母亲报告称，暴露于各种抗组胺药的婴儿中有10%出现了烦躁和肠绞痛症状，1.6%的婴儿出现了嗜睡。所有反应均未需要医疗关注，且没有患者使用bepotastine。 ◉ 对泌乳和母乳的影响：在非哺乳期妇女和产后早期妇女中，通过注射给予相对较高剂量的抗组胺药可以降低基础血清催乳素。然而，哺乳诱导的催乳素分泌不受产后母亲抗组胺药预处理的影响。已建立哺乳的母亲催乳素水平可能不会影响她的哺乳能力。低剂量的眼部bepotastine不太可能对血清催乳素有相同的影响。

◉ Summary of Use during Lactation:There are no reports of infants breastfed during maternal therapy with bepotastine. Because absorption from the eye is limited, bepotastine would not be expected to cause any adverse effects in breastfed infants. To substantially diminish the amount of drug that reaches the breastmilk after using eye drops, place pressure over the tear duct by the corner of the eye for 1 minute or more, then remove the excess solution with an absorbent tissue. ◉ Effects in Breastfed Infants:Relevant published information on bepotastine was not found as of the revision date. In one telephone follow-up study, mothers reported irritability and colicky symptoms in 10% of infants exposed to various antihistamines and drowsiness was reported in 1.6% of infants. None of the reactions required medical attention and none of the patients were using bepotastine. ◉ Effects on Lactation and Breastmilk:Antihistamines in relatively high doses given by injection can decrease basal serum prolactin in nonlactating women and in early postpartum women. However, suckling-induced prolactin secretion is not affected by antihistamine pretreatment of postpartum mothers. The prolactin level in a mother with established lactation may not affect her ability to breastfeed. Low ophthalmic doses of bepotastine are unlikely to have the same effect on serum prolactin.

来源:Drugs and Lactation Database (LactMed)

反应信息

• 作为产物：
  描述：

  bepotastine 在 溶剂黄146 作用下， 反应 4.0h， 以48%的产率得到
  参考文献：
  名称：

  ピペリジン誘導体のラセミ化方法

  摘要：

  题目：提供一种有效地将（R）-哌嗪衍生物转化为混合体的方法，以及从该混合体中制备（S）-哌嗪衍生物的方法。 解决方案：通过将式（1）中表示的（R）-哌嗪衍生物与酸接触，制备哌嗪衍生物的混合体。（其中R1为H、C2-7的酰基、C2-15的醇酯基、C4-20的醇酯基或C4-20的羟酰基；X为卤素原子） 选择图：无。

  公开号：

  JP2019001736A

文献信息

• METHOD OF SYNTHESIZING BEPOTASTINE OR BENZENESULFONIC ACID SALT THEREOF AND INTERMEDIATES USED THEREIN
  申请人：EVERLIGHT USA, INC.

  公开号：US20140046068A1

  公开（公告）日：2014-02-13

  The present invention relates to a novel method of synthesizing bepotastine or its benzenesulfonic acid salt and novel intermediates used therein. The present invention uses L-α-hydroxy acid for chiral resolution to form an L-α-hydroxy acid salt of a compound represented by the following formula (VII-1), so as to synthesize bepotastine or its benzenesulfonic acid salt in high optical purity.

  本发明涉及一种合成贝泼替丁或其苯磺酸盐的新方法以及其中使用的新中间体。本发明利用L-α-羟基酸进行手性分离，形成由以下式（VII-1）所代表的化合物的L-α-羟基酸盐，从而在高光学纯度下合成贝泼替丁或其苯磺酸盐。
• Acid addition salt of optically active piperidine compound and process for preparing the same
  申请人：UBE INDUSTRIES, LTD.

  公开号：US20020026054A1

  公开（公告）日：2002-02-28

  The present invention is to provide a benzenesulfonic acid salt and a benzoic acid salt of (S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butanoic acid represented by the formula (I): 1 wherein * represents an asymmetric carbon, which are excellent in antihistaminic activity and anti-allergic activity, and a process for producing the same.

  本发明提供了一种苯磺酸盐和苯甲酸盐，其化学式为（I）：其中*代表不对称碳，该化合物具有出色的抗组胺活性和抗过敏活性，同时还提供了其制备方法。
• ACID-ADDITION SALTS OF OPTICALLY ACTIVE PIPERIDINE COMPOUND AND PROCESS FOR PRODUCING THE SAME
  申请人：Ube Industries, Ltd.

  公开号：EP0949260B1

  公开（公告）日：2002-05-22
• US6307052B1
  申请人：——

  公开号：US6307052B1

  公开（公告）日：2001-10-23
• US6780877B2
  申请人：——

  公开号：US6780877B2

  公开（公告）日：2004-08-24